Purpose
|
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec?), another tyrosine kinase inhibitor currently used as a first-line treatment.
|
Characteristics
|
Tradename: AMN-107 Source of Compound: synthetic Target: Bcr-Abl inhibitor,Mast/stem cell GFR Kit agonist Receptor: Bcr-Abl ,Mast/stem cell GFR Kit Status: FDA
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99.00?%
|
Formula
|
C28H22F3N7O
|
Solubility
|
DMSO 27 mg/Ml,Water <1 mg="" ml="" <="" td="">
1> |